Myriad Genetics Inc (NAS:MYGN)
$ 25.29 0.7 (2.84%) Market Cap: 2.29 Bil Enterprise Value: 2.33 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 76/100

Myriad Genetics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 06:15PM GMT
Release Date Price: $16 (-1.96%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hey, guys. Good afternoon. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at Morgan Stanley. Before we begin, I would like to remind our listeners and folks in the room for -- of the important disclosure information can be found at morganstanley.com/researchdisclosures. And if you have any questions on those, you can chat to a salesperson. It's my pleasure today to host Myriad Genomics -- Genetics, sorry. I'm speaking on behalf of the company. I have Paul Diaz, CEO. Thank you so much, Paul, for coming in.

Questions & Answers

Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Maybe to start Myriad has come a long way since where the company was back in 2019. Just bring us a picture for what the asset looked like when you got there 3 years ago. What's changed since? And what sort of stays the same?

Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director

Well, from day

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot